Proceedings · Session S-339 · filed November 19, 2026

Corporate & Industrial R&DSession paper

Roquette previews two-ingredient HPMC capsule for 2027 launch

Roquette previewed the two-ingredient Quali-V Pure HPMC capsule at CPHI Milan in October 2026, with a 2027 launch planned and no comparative data in the interview.

By Tom Whitfield4 min read840 words

Summary

  • Quali-V Pure has two stated components—HPMC and water—with no carrageenan or other gelling agents.
  • Roquette previewed the capsule at CPHI Milan in October 2026 and plans a commercial launch in 2027.
  • Roquette claims consistent dissolution across varying pH conditions and low moisture content but supplied no numerical specifications.
  • The interview disclosed no development funding, sample size, comparator, test method or independent validation.
  • Chiara Bergerone became deputy CEO of Roquette’s Health & Pharma Solutions Business Unit in 2026.
<![CDATA[HPMC Capsule Offers Simpler Formulation]]>
Figure<![CDATA[HPMC Capsule Offers Simpler Formulation]]> — stevepb / pixabay

Roquette says it plans a 2027 commercial launch for Quali-V Pure, a hydroxypropyl methylcellulose (HPMC) capsule made with only HPMC and water, after previewing it at CPHI Milan in October 2026. The capsule contains no gelling agents such as carrageenan, a design intended to simplify excipient declarations and formulation and regulatory considerations.

Chiara Bergerone, who became deputy CEO of Roquette’s Health & Pharma Solutions Business Unit in 2026, spoke for the product and described it as the next stage in the company’s established Quali-V HPMC capsule portfolio. “Quali-V Pure answers that with just HPMC and water,” she said.

What changes with a two-ingredient capsule?

Quali-V Pure uses plant-based HPMC as an alternative to animal-derived gelatin. Roquette also says its low moisture content suits moisture-sensitive and hygroscopic formulations. For formulation teams, the low-moisture positioning puts moisture control and hygroscopic-fill compatibility on the evaluation list. The interview gave no numerical moisture specification or supporting stability dataset.

What evidence supports the performance claims?

Roquette says Quali-V Pure is designed to dissolve consistently across different pH conditions, addressing variability concerns associated with some capsule systems in the gastrointestinal tract. The interview did not identify the pH range, dissolution endpoint, test method, comparator capsule, batch count or replicate number.

Bergerone offered no measured release values, so the claim remains a design target rather than a published performance result. Nor did she provide a head-to-head comparison with existing HPMC or gelatin capsules, despite that being the first question in the interview.

Roquette disclosed no numerical low-moisture figure, moisture uptake rate or shelf-life period. It did not disclose development funding, and the interview named no independent laboratory or third-party validation for the capsule. Researchers should treat the dissolution and moisture statements as unquantified supplier claims until Roquette publishes supporting data.

How does the capsule affect formulation and regulatory work?

“We are hearing a clear demand from formulators for simpler, shorter excipient compositions, both for formulation and regulatory reasons,” Bergerone said. The company links the shorter formulation to that demand, but the interview did not identify any regulatory filing, approval or market-specific acceptance for Quali-V Pure.

For R&D and procurement teams, the proposed value proposition centers on fewer excipient declarations and the potential to streamline formulation and regulatory work. Roquette disclosed no price, development cost or quantified saving, so budget impact remains open.

Roquette says excipients and processing technologies influence the final dosage form, so early consideration of manufacturability, stability, regulatory requirements and patient acceptability can help developers streamline development, reduce risk and accelerate the path from concept to market. It presents high-quality ingredients, formulation expertise and early customer collaboration as the route for managing those technical risks.

Why does patient experience shape the business case?

Bergerone framed drug-delivery development as a balance between technical performance and patient experience. Her answer says developers must consider whether a product delivers its intended function, how easily and comfortably patients take it, and whether the dosage form meets patient needs. She links those choices to adherence and positive outcomes.

Roquette describes convenient, accessible and easy-to-administer dosage forms as growing differentiators. That was a general market view, however: the interview supplied no Quali-V Pure patient study, adherence rate or product-specific acceptance data.

What did CPHI reveal about demand?

At CPHI Milan, Bergerone said reconnecting with customers and partners and hearing directly about their formulation problems mattered most to her. She said the discussions went beyond individual products to evolving customer needs and collaboration on increasingly complex challenges.

“The conversations at our booth confirmed that customers are looking for exactly this kind of simplicity,” Bergerone said. The comments indicate interest in the capsule concept, but the interview gave no survey size, customer count or quantified level of demand.

Where does Quali-V Pure fit in the portfolio?

The capsule is planned for a 2027 commercial launch and complements, rather than replaces, Roquette’s established Quali-V HPMC capsule portfolio. For portfolio managers, it adds a plant-based alternative to animal-derived gelatin designed around a shorter formulation, with the commercial comparison still resting on evidence not supplied in the interview.

Bergerone’s background spans industrial and healthcare product development. She led complex specialty-chemicals projects across Europe and the United States before moving into healthcare and MedTech, where she held general-management roles covering commercial performance and innovation, team building and solution launches.

She now leads commercial, strategic marketing, product line management and business development for Roquette’s Health and Pharma Solutions unit, which sets growth strategy and its mission to deliver differentiated pharmaceutical solutions for patients worldwide. Her degrees include Biomedical Materials Engineering from Politecnico di Torino, Physics from Grenoble INP and an MBA from Collège des Ingénieurs in Paris.

Before the planned 2027 launch, formulators will need the numerical dissolution profile, moisture specification and stability and manufacturability evidence that this interview omitted. Until Roquette supplies that evidence, simplicity is the capsule’s clearest stated feature.

via pharmtech.com (Source)

Filed under

  • hpmc-capsules
  • pharmaceutical-excipients
  • drug-delivery
  • formulation-development
  • quali-v-pure
Share this article:

More from Tom Whitfield

Tom Whitfield

Show full bio

Senior reporter covering technology and product news in research and development at Hypothesis Wire.

272 articles

References

  1. ARPA-H Commits Up to $87 Million to Room-Temperature Cell Therapy Storage
  2. Scaling Oral Peptides: Alcami Scientist Maps GLP-1 Manufacturing Hurdles
  3. Four CDMOs Detail How Robust Formulations Are Actually Proven
  4. AI accountability, FDA shifts and a $1.15 billion deal
  5. FDA Approves Pimicotinib for TGCT on 56% Response Rate

« Previous article